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Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue tumor composed of
myofibroblasts with an inflammatory infiltrate. Various gene fusions involving the anaplastic
lymphoma kinase (ALK) gene at chromosome 2p23 have been described in IMT, suggesting a
neoplastic etiology. The ALK rearrangement is reportedly more common in children and there
are only rare IMTs in adults with genetic information. This study represents the largest series of
lesions designated as IMT on morphologic grounds with comparative ALK IHC and FISH
analysis. Sixteen IMTs were retrieved from the UNM and UVa archives. Inclusion criteria
required spindle cells, inflammatory cells and thorough clinical, histological and
immununohistochemical exclusion of other diagnostic possibilities. IHC was performed on each
of the sixteen cases using a monoclonal ALK1 antibody and evaluated for cytoplasmic and
nuclear stain intensity and distribution. FISH was performed on tissue microarray sections using
the ALK breakapart genomic marker. MetaSystems automated FISH analyzer detected signal
patterns on interphase nuclei and results were interpreted on a Meta workstation. Patients ranged
in age from 2-70 years (mean 48; median 43). IHC and FISH were successful on 16/16 and
10/16 cases, respectively. One case was positive for ALK rearrangement by FISH. This case
also demonstrated diffusely strong cytoplasmic and focally strong nuclear immunopositivity.
One case showed diffusely strong cytoplasmic ALK immunopositivity without gene
rearrangement by FISH. ALK overexpression (IHC) and genomic rearrangements (FISH) are
uncommon in our series of IMTs. This may be related to the older age of patients in our study.
ALK IHC negative cases did not show ALK gene rearrangement by FISH. Further investigation
is warranted to determine if ALK positive lesions represent a different, more biologically
aggressive entity, necessitating a distinct designation.
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Introduction
Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue tumor arising
predominately in children and young adults.1-2 IMTs are composed of spindle cell
myofibroblastic proliferations with a prominent infiltrate of plasma cells, lymphocytes and
eosinophils. The entity of IMT arouse in 19951 from the recognition of similarities among a
variety of lesions with myofibroblasts and inflammatory cells including: inflammatory
pseudotumor of the lung, plasma cell granuloma, postoperative spindle cell nodule,
pseudosarcomatous myofibroblastic proliferation, and atypical fibromyxoid tumor.3 There has
been ongoing debate over the reactive versus neoplastic nature of the lesion. However, the
discovery of a genetic translocation involving the ALK gene (anaplastic lymphoma kinase) on
chromosome 2p23 argues for a neoplastic process in at least a subset of lesions.4
ALK was first identified as an important translocated gene in anaplastic large cell
lymphoma (ALCL) in 1994. The main translocation in ALCL is t(2;5)(p23;q35) where the ALK
gene located on 2p23 is fused to the NPM (nucleophosmin) gene at 5q35. ALK encodes for a
tyrosine kinase and NPM for a nucleolar phosphoprotein. The resulting fusion gene encodes a
chimeric protein which is a constitutively active tyrosine kinase.5 The discovery of ALK
translocations in a subset of IMTs indicates that inappropriate activation of the ALK signaling
pathway may be a critical step in the neoplastic transformation of myofibroblasts.3
Several ALK fusion genes have been reported in IMTs. Molecular studies have
identified ALK fusion involving tropomyosin-3 and -4 (TPM-3 and -4), the clathrin heavy chain
(CLTC), cysteinyl-tRNA synthetase (CARS), and Ran-Binding Protein 2 (RANBP2).6-9
Lawrence et al has demonstrated that the TPM3-ALK and TPM4-ALK fusion proteins in IMT
are phosphorylated and activated.6 It is postulated that the other fusion partners also result in a
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constitutively active tyrosine kinase conferring tumorgenesis. The discovery of ALK
translocations in IMTs was an important step in understanding the pathophysiology of the tumor;
however, only 30-50% of IMTs are found to have detectable ALK rearrangements. In addition,
those with ALK rearrangements are almost exclusively in children. Coffin et al reported 11 of
40 cases positive by immunohistochemistry (IHC) with ALK antibody and all patients with ALK
positivity were younger than 10 years.10 Lawrence et al reported a slightly higher rate using
cytogenetic methods with approximately 50% (7 out of 11) containing ALK rearrangements. All
the negative cases were in adults older than 40 years.6
Along with genetic heterogeneity, IMTs also exhibit morphologic and clinical variation.
The various morphologic differences led to the definition of three different histological patterns
including: nodular fasciitis-like, fibrous histiocytoma-like and desmoid-like. According to
Coffin et al, histological pattern does not have a clear correlation with clinical behavior.1 In
addition, thus far ALK immunoreactivity has not been linked with specific histological features.
Given that most data on ALK gene rearrangement in IMTs involves children and young
adults we investigated IMTs in a predominately adult population. In addition, most studies
require ALK immunopositivity as a prerequisite to perform genetic studies for ALK gene
mutations, even though there is extreme variability in staining in cases with known ALK gene
rearrangements. Griffen et al described three cases with known ALK gene rearrangement where
ALK immunopositivity ranged from focally weak to diffusely strong.11 We investigated ALK
IHC and ALK gene rearrangement by FISH on all cases of IMT to further assess the sensitivity
of ALK IHC in predicting genetic abnormalities. Lastly, we assessed the efficacy of utilizing a
tissue microarray (TMA) for detecting ALK gene rearrangements on interphase nuclei using a
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FISH probe. TMAs allow for the evaluation of multiple lesions on one slide, thus having the
potential to greatly decrease study costs and time.
Materials and Methods
Selection
The University of New Mexico and University of Virginia surgical pathology files were searched
for archival, formalin-fixed, paraffin-embedded cases of inflammatory myofibroblastic tumor.
Inclusion criteria required spindle cells and inflammatory cells along with thorough clinical,
histological and immunohistochemical exclusion of other diagnostic possibilities. A total of
sixteen cases were retrieved.
ALK Immunohistochemistry
ALK1 antibody staining was performed on 4-μm sections of formalin-fixed, paraffin-embedded
tissue for all sixteen cases using monoclonal mouse antihuman ALK antibody (Dako,
Carpinteria, CA). Staining was detected using the avidin-biotin immunoperoxidase technique.
The primary antibody was omitted for the negative control. Sections of appropriate tissues
containing the targeted antigen served as positive controls. Antigenic reactions were interpreted
semiquantitatively for both distribution and intensity. Distribution was scored as rare cells (05%), focal (6-50%), diffuse (51-95%), or complete (>95%). Intensity was scored subjectively by
multiple authors (KR, LC, KC) as 0, +1, +2, or +3.
FISH
FISH was performed on tissue microarray (TMA) sections. To prepare the TMA, core tissue
biopsies (2mm diameter; height 2-4 mm) were taken from each of the sixteen “donor” paraffinembedded blocks containing IMT. The cores were obtained by punching the area of the donor
block with a thin-walled stainless steel tube shaped like a cork borer. A hematoxylin and eosin-
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stained section overlying the surface of the donor block was used as a guide to identify regions
positive for IMT. The core taken from each donor block was transferred into a recipient tissue
microarray block capable of holding 21 cases, including a positive control. Tissue microarray
sections were cut at 4-5 micron intervals for FISH.
FISH was performed using the Vysis LSI ALK dual color break apart rearrangement probe. The
probe contained two differently labeled probes on opposite sides of the breakpoint of the ALK
gene. An approximately 250 kb probe for the telomeric side of the ALK breakpoint was labeled
with SpectrumOrange and the centromeric probe was approximately 300 kb and labeled with
SpectrumGreen. The sections were pretreated with a Vysis VP-2000 tissue processor following
standard protocol. Ten ml of the ALK rearrangement probe was then applied to each tissue
section, covered with a 22 mm2 coverslip and sealed. The slides were placed on a Vysis Hybrite,
co-denatured with the probe at 73 degrees C for 6 minutes and allowed to hybridize at 37 degrees
C for 16-20 hours. Hybridized slides were then washed and counterstained with DAPI. The
fluorescent signals in interphase nuclei on the hybridized slides were then examined and
analyzed on the MetaSystems computer and subsequently validated by the investigators (KC,
KR).
Results
Patients ranged in age from 2-70 years (median 48; mean 43). Lesions were located in the
cervix, lung, bladder, soft tissue, breast, liver and esophagus.
ALK Immunohistochemistry
Immunohistochemical staining for ALK demonstrated positive nuclear staining in the
myofibroblastic cells in one case and cytoplasmic staining in two of the sixteen cases. The case
with nuclear staining (focal, +3) was located in the cervix and also demonstrated diffusely strong
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(+3) cytoplasmic staining. The second case showing solely cytoplasmic staining was located in
the bladder was also diffusely strong (+3). The remaining fourteen cases did not show any
evidence of cytoplasmic or nuclear staining.
FISH
FISH was successful in ten of the sixteen cases. The six unsuccessful cases either experienced
tissue drop-out during TMA processing or exhibited marked background nonspecific
fluorescence prohibiting adequate evaluation. One of the ten successful cases was positive for
ALK break apart gene rearrangement. The positive FISH case was located in the cervix and also
demonstrated diffusely strong (+3) cytoplasmic and focally strong (+3) nuclear staining.
Please refer to Table 1.
Discussion
Inflammatory myofibroblastic tumor is a relatively rare soft tissue tumor composed of a
spindle cell myofibroblastic proliferation with infiltrating inflammatory cells including
lymphocytes, plasma cells and eosinophils. It was recognized as a distinct entity in 19951,
however, the uncertainty regarding its neoplastic versus reactive nature remains a topic of
debate. The discovery of a clonal abnormality involving the ALK gene on 2p23 in several cases
of IMTs favors a neoplastic origin in a subset of lesions.6-9 In addition to a clonal population of
cells, some IMTs are locally aggressive, recurrent, invasive, and rarely metastatic further
favoring a neoplastic process.11 The clinical behavior varies among individuals but has been
termed as a tumor with indeterminate or low malignant potential.12
ALK overexpression (IHC) and genomic rearrangements (FISH) are uncommon in our
series of IMT. This may be a result of the older age of patients in our study (mean 48; median
43). Our findings correlate with previous reports stating that most cases of IMT with genetic

7

abnormalities are found in children and young adults6,10. IMTs in children with ALK gene
rearrangements may represent a separate entity from ALK negative lesions found in adults.
Further research into the clinical progression of IMTs found in children and adults is warranted
in order to further understand and better classify IMTs.
In our study ALK immunopositivity correlated with ALK gene status, except for in one
case. This case was located in the bladder and demonstrated diffusely strong cytoplasmic
staining without evidence of ALK gene rearrangement by FISH. ALK overexpression may be a
result of a genetic mutation unable to be detected by the ALK break apart probe used in the
study. Such findings bring up the possibility of additional ALK gene mutations, other than gene
fusion, resulting in IMT tumorgenesis. Further molecular studies may be indicated to determine
the existence of other ALK gene mutations in IMTs.
All ALK immunonegative cases were also negative for ALK gene rearrangements by
FISH. In addition, the one case positive for gene rearrangement by FISH also had diffusely
strong cytoplasmic and focally strong nuclear ALK immunopositivity. Thus, ALK IHC is a
sensitive marker for detecting ALK gene rearrangement in IMTs. This is useful since IHC is
much cheaper, more accessible and has a shorter turn around time than FISH at many
institutions.
Two problems experienced in our study limiting the amount of FISH data available for
analysis included TMA tissue drop-out and non-specific binding of probe to stromal tissue.
Tissue drop-out occurs when a core falls out of the recipient block during sectioning. One
possible remedy for this situation is warming of the recipient block once all cores have been
inserted. This allows for the paraffin of the recipient block and cores to slowly melt and congeal
producing a more cohesive and less fragile block during sectioning. Non-specific binding of
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probe to stromal tissue caused inappropriate fluorescence and inability to adequately evaluate for
ALK break apart in a few cases. This has the potential to be a recurring problem since many
cases of IMT have a large stromal tissue component. By selecting areas of the lesion with a high
myofibroblast population the amount of non-specific binding is likely to be reduced.
Additionally, by placing more than one core from different locations in the same lesion into the
recipient block increases the likelihood of producing analyzable results. In the cases where the
ALK breakapart probe was adequately hybridized MetaSystems was effective in detecting
signals.
Lastly, it is well known that IMT is a heterogeneous tumor. One question that arises is
whether the 2 mm core in the TMA is representative of the entire lesion. It can by hypothesized
that IMTs containing an ALK fusion gene should exhibit this mutation in all myofibroblasts
present. As a result, a 2 mm core from the lesion should be adequate to detect the ALK gene
rearrangement by FISH. As mentioned above, in those cases where a large amount of stromal
tissue is present more than one core from each lesion can be placed into the recipient block to
guarantee adequate representation of the lesion. Even by placing up to four cores from each
lesion into the recipient block, five lesions can be represented. By doing this, the cost of FISH
reagents is still markedly decreased.
In conclusion, the results of this study support the theory that the majority of IMTs with
ALK gene rearrangement are found in children and young adults. Our findings also support the
idea that a subset of lesions with histology described as IMT are neoplastic rather than reactive.
More research into the clinical progression and behavior of ALK positive IMTs found in children
and ALK negative lesions found in adults may help further understand and subclassify IMTs. In
our study ALK IHC was a sensitive marker for identifying lesions positive for ALK gene
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rearrangement by FISH. This finding is useful for diagnostic purposes since IHC costs less and
is more accessible at most institutions. Additional studies linking histology, gene status, and
clinical behavior are needed in order to better understand this complicated lesion.
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Table 1
ALK IHC and FISH

ALK IHC
cytoplasm
ALK IHC nuclear
ALK FISH status

Cervix
(1)

Lung
(5)

Bladder
(2)

Soft Tissue
(5)

Breast
(1)

Liver
(1)

Esophagus
(1)

1/1 3+ D

0/5

1/2 3+ D

0/5

0/1

0/1

0/1

1/1 3+ F
Positive

0/5
Negative

0/2
Neg (1)
ND (1)

0/5
Neg (3)
ND (2)

R 1+
ND

0/1
ND

0/1
ND

D = diffuse; F = focal; R = rare; ND = no data
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